fentanyl has been researched along with Dysphagia in 6 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Excerpt | Relevance | Reference |
---|---|---|
"Failure to recognize the impact of various situations described throughout this work, including the bioavailability due to loss of oral route, due to pharmacokinetics and pharmacodynamics of the various drugs, either in the context of the impaired metabolism or excretion, or in due to pharmacological interactions, conditions a serious risk of subtreatment of pain and consequent impact in terms of quality of life." | 2.61 | [Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review]. ( Brás, M; Fragoso, M; Vieira, C, 2019) |
" Eighty per cent of patients were not asked about their ability to swallow solid, oral dosage forms by their physician." | 1.40 | Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. ( Carlson, DR; Kopecky, EA; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Taylor, R; Varanasi, RK, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Balko, RA | 1 |
Katzka, DA | 1 |
Murray, JA | 1 |
Alexander, JA | 1 |
Mara, KC | 1 |
Ravi, K | 1 |
Vieira, C | 1 |
Brás, M | 1 |
Fragoso, M | 1 |
Pergolizzi, JV | 1 |
Taylor, R | 1 |
Nalamachu, S | 1 |
Raffa, RB | 1 |
Carlson, DR | 1 |
Varanasi, RK | 1 |
Kopecky, EA | 1 |
Kuczkowski, KM | 1 |
Goldsworthy, M | 1 |
Smiley, RM | 1 |
Moore, RP | 1 |
Currier, DS | 1 |
Levin, KR | 1 |
Campbell, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills[NCT03588806] | Phase 4 | 11 participants (Actual) | Interventional | 2018-05-01 | Terminated (stopped due to Study halted permanently and will not resume; participants are no longer being examined or receiving intervention.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Pill swallowing difficulty will be measured via a 0-10 scale with 0 being no trouble at all and 10 being the greatest difficulty possible. Responses will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Baseline covers current opioid medication, and week 6 covers Xtampza ER.
Intervention | units on a scale (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | -5.7 |
"Percent change in pain intensity (in the last 24 hours) from baseline to the end of the study averaged over the last 7 days before clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
Intervention | percent change (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | 12.5 |
"Percent change in pain intensity (in the past 7 days) from baseline to the end of the study at clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
Intervention | percent change (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | 9.3 |
"Opioid medication satisfaction will be measured via a 0-10 scale with 0 being not satisfied at all and 10 being completely satisfied. Responses will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Recorded baseline for current opioid medication and in week 6 for Xtampza ER.
Intervention | units on a scale (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | 2.8 |
The subject's impression of the impact of the treatment on their pain and function will be measured with a 7-item scale (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved). Responses will be summarized as individual mean scores at clinic visit 4 (week 6). (NCT03588806)
Timeframe: Recorded in week 6.
Intervention | units on a scale (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | 1.2 |
"The Pain Interference questions (#25-28) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Not at all and 5 being Very much. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Pain Interference T-Scores will be summarized as the change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
Intervention | T-Score (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | -3.6 |
"The Physical Function questions (#1-4) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 5 being Without any difficulty and 1 being Unable to do. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Physical Function T-Scores will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
Intervention | T-Score (Mean) |
---|---|
Xtampza ER (Oxycodone) Treatment | 0.7 |
"The Depression (#9-12), Anxiety (#5-8), Satisfaction with Social Roles (#21-24), and Sleep Disturbance (#17-20) questions from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Never and 5 being Always. Responses for each section will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. These T-Scores will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
Intervention | T-Score (Mean) | |||
---|---|---|---|---|
Depression | Anxiety | Satisfaction with Social Roles | Sleep Disturbance | |
Xtampza ER (Oxycodone) Treatment | -0.4 | -1.7 | 1.1 | -3.7 |
1 review available for fentanyl and Dysphagia
Article | Year |
---|---|
[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Cancer Pain; Codeine; Deglutition Disorders | 2019 |
5 other studies available for fentanyl and Dysphagia
Article | Year |
---|---|
Same-day opioid administration in opiate naïve patients is not associated with opioid-induced esophageal dysfunction (OIED).
Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Intravenous; Chest Pain; Conscious Sedation; Deglutiti | 2021 |
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives.
Topics: Analgesics, Opioid; Child; Chronic Pain; Data Collection; Deglutition Disorders; Fentanyl; Humans; M | 2014 |
Transient aphonia and aphagia in a parturient after induction of combined spinal-epidural labor analgesia with subarachnoid fentanyl and bupivacaine.
Topics: Adjuvants, Anesthesia; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Aphon | 2003 |
Loss of gag reflex and swallowing ability after administration of intrathecal fentanyl.
Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Deglutition Disorders; Female; Fentanyl; Gagging; | 2007 |
Dysphagia with intrathecal fentanyl.
Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Bupivacaine; Deglutition Disorders; Female; Fenta | 1997 |